title: Five-Year Survival Data Demonstrating Durable Responses From a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma.
mesh_terms: D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000628:therapy*; D033581:Stem Cell Transplantation / Q000379:methods; D016019:Survival Analysis
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin